Article
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2025
Kacimi Salah Eddine O, Dehais Caroline, Feuvret Loïc, Chinot Olivier, Carpentier Catherine, Bronnimann Charlotte, Vauleon Elodie, Djelad Apolline, Cohen-Jonathan Moyal Elizabeth, Langlois Olivier, Campone Mario, Ducloie Mathilde, Noel Georges, Cuzzubbo Stefania, Taillandier Luc, Ramirez Carole, Younan Nadia, Menei Philippe, Dhermain Frédéric, Desenclos Christine, Ghiringhelli François, Bourg Veronique, Ricard Damien, Faillot Thierry, Appay Romain, Tabouret Emeline, Nichelli Lucia, Mathon Bertrand, Thomas Alice, Tran Suzanne, Bielle Franck, Alentorn Agusti, Iorgulescu J Bryan, Boëlle Pierre-Yves, Labreche Karim, Hoang-Xuan Khê, Sanson Marc, Idbaih Ahmed, Figarella-Branger Dominique, Ducray François, Touat Mehdi
Abstract excerpt
PURPOSE: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3IDHmt/Codel) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) and temozolomide (TMZ) remains unclear given the lack of randomized trial data comparing both regimens. METHODS:...
Topics
Join the communities discussing this publication.